The trajectory of the erectile dysfunction drug presents a intricate picture for investors. While the initial introduction generated substantial gains, the lapse of its patent opened the avenue to off-brand https://enrollbookmarks.com/story21573796/the-copyright-and-the-pharmaceutical-industry-a-risky-bet